[go: up one dir, main page]

MX2014015884A - Compuestos antivirales. - Google Patents

Compuestos antivirales.

Info

Publication number
MX2014015884A
MX2014015884A MX2014015884A MX2014015884A MX2014015884A MX 2014015884 A MX2014015884 A MX 2014015884A MX 2014015884 A MX2014015884 A MX 2014015884A MX 2014015884 A MX2014015884 A MX 2014015884A MX 2014015884 A MX2014015884 A MX 2014015884A
Authority
MX
Mexico
Prior art keywords
antivirals
triazole compounds
compounds
formula
variables
Prior art date
Application number
MX2014015884A
Other languages
English (en)
Inventor
Klaus Klumpp
Joseph Anthony Bilotta
Eric Mertz
Shawn David Erickson
Stephen Deems Gabriel
Zhi Chen
Elbert Chin
Qingjie Ding
Han Ma
Jean-Marc Plancher
Robert James Weikert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014015884A publication Critical patent/MX2014015884A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe compuestos de la Fórmula I: (ver Fórmula) en donde las variables en la Fórmula I se definen como se describen en la presente. También se describen composiciones farmacéuticas que contienen tales compuestos y métodos para utilizar los compuestos de la Fórmula I en la prevención o el tratamiento de la infección del VHC.
MX2014015884A 2012-07-06 2013-07-03 Compuestos antivirales. MX2014015884A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261668547P 2012-07-06 2012-07-06
PCT/EP2013/063980 WO2014006066A1 (en) 2012-07-06 2013-07-03 Triazole compounds as antivirals

Publications (1)

Publication Number Publication Date
MX2014015884A true MX2014015884A (es) 2015-03-19

Family

ID=48793192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015884A MX2014015884A (es) 2012-07-06 2013-07-03 Compuestos antivirales.

Country Status (10)

Country Link
US (2) US20140010783A1 (es)
EP (1) EP2870143B1 (es)
JP (1) JP6039067B2 (es)
KR (1) KR20150029016A (es)
CN (1) CN104428289B (es)
BR (1) BR112015000011A2 (es)
CA (1) CA2873512A1 (es)
MX (1) MX2014015884A (es)
RU (1) RU2015102610A (es)
WO (1) WO2014006066A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150109451A (ko) * 2013-01-23 2015-10-01 에프. 호프만-라 로슈 아게 항바이러스성 트라이아졸 유도체
CA2898162A1 (en) * 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag N-heteroaryl substituted aniline derivatives as hcv-antivirals
KR20150113203A (ko) 2013-03-05 2015-10-07 에프. 호프만-라 로슈 아게 항바이러스 화합물
BR112015021001A2 (pt) * 2013-03-05 2017-07-18 Hoffmann La Roche compostos antivirais
CN105008350B (zh) * 2013-03-05 2018-05-08 弗·哈夫曼-拉罗切有限公司 抗病毒化合物
CA2898107A1 (en) 2013-03-06 2014-09-12 F. Hoffmann-La Roche Ag Antiviral compounds
CN106432031A (zh) * 2016-09-09 2017-02-22 中国药科大学 苯甲酸三氮唑类抗流感病毒化合物及其制备方法和用途
CN109422664B (zh) * 2017-08-23 2022-02-18 中国科学院福建物质结构研究所 一类干扰素调节剂及其制备方法和用途
EP4423090A2 (en) * 2021-10-26 2024-09-04 Vasocardea, Inc. Antagonists of gpr39 protein
EP4457218A1 (en) * 2021-12-30 2024-11-06 Collaborations Pharmaceuticals, Inc. New antiviral triazole derivatives, their synthesis and their use for treatment of mammalian viral infections
WO2025080695A1 (en) * 2023-10-10 2025-04-17 Collaborations Pharmaceuticals, Inc. 1-sulfonyl-3-amino-1h-1,2,4-triazoles as yellow fever virus inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CA2250698A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Para-substituted phenylpropanoic acid derivatives as integrin antagonists
EP0902782A1 (en) 1996-04-23 1999-03-24 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
SE508697C2 (sv) 1996-07-19 1998-10-26 Ericsson Telefon Ab L M Förfarande och anordning för tidskontinuerlig filtrering i digital CMOS-process
DE69709671T2 (de) 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
JP4452401B2 (ja) 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルス阻害ペプチドアナログ
CA2338490A1 (en) 1998-07-27 2000-02-10 Sergio Altamura Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2002523371A (ja) 1998-08-21 2002-07-30 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法
CN1324250A (zh) 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
CN1324212A (zh) 1998-09-25 2001-11-28 维洛药品公司 治疗或预防病毒感染及有关疾病的方法
EA004141B1 (ru) 1999-03-19 2004-02-26 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фермента impdh
GB9918180D0 (en) * 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
US6518253B1 (en) * 1999-11-19 2003-02-11 Robert Tam Treatment of viral infections using the L-isomer of ribavirin
EP1292310A1 (en) 2000-05-10 2003-03-19 SmithKline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1355889B1 (en) * 2000-12-22 2006-06-07 Ortho-McNeil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
DE10123586A1 (de) * 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
EA007484B1 (ru) 2001-06-11 2006-10-27 Вирокем Фарма Инк. Соединения и способы лечения или предупреждения инфекций flavivirus
US6887877B2 (en) 2001-06-11 2005-05-03 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
ATE370137T1 (de) 2001-11-02 2007-09-15 Glaxo Group Ltd 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
WO2004032875A2 (en) * 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
CN1738615A (zh) * 2002-11-15 2006-02-22 沃泰克斯药物股份有限公司 用作蛋白质激酶的抑制剂的二氨基三唑类
US20090018150A1 (en) * 2003-07-24 2009-01-15 Asterand Uk Limited 5-Ht2b Receptor Antagonists
DE602005017582D1 (en) 2004-01-30 2009-12-24 Medivir Ab Hcv ns-3 serine protease inhibitoren
CA2555825A1 (en) * 2004-02-11 2005-08-25 Janssen Pharmaceutica N.V. Process for the preparation of substituted triazole compounds
US7884119B2 (en) * 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
WO2007118149A2 (en) * 2006-04-07 2007-10-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009003077A1 (en) 2007-06-27 2008-12-31 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function
WO2010108187A2 (en) * 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
CA2784765A1 (en) * 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic triazole derivatives as gamma secretase modulators
KR20190120430A (ko) * 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
US9434745B2 (en) * 2012-05-23 2016-09-06 Savira Pharmaceuticals Gmbh 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

Also Published As

Publication number Publication date
US20150307461A1 (en) 2015-10-29
CN104428289A (zh) 2015-03-18
CN104428289B (zh) 2017-06-23
WO2014006066A1 (en) 2014-01-09
US20140010783A1 (en) 2014-01-09
JP2015525743A (ja) 2015-09-07
EP2870143B1 (en) 2017-05-17
KR20150029016A (ko) 2015-03-17
HK1208455A1 (en) 2016-03-04
CA2873512A1 (en) 2014-01-09
JP6039067B2 (ja) 2016-12-07
EP2870143A1 (en) 2015-05-13
BR112015000011A2 (pt) 2017-06-27
RU2015102610A (ru) 2016-08-27

Similar Documents

Publication Publication Date Title
MX2014015884A (es) Compuestos antivirales.
MX2015011193A (es) Compuestos antivirales.
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
NZ703064A (en) Inhibitors of hepatitis c virus
IN2015DN01156A (es)
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
PH12015501385A1 (en) Autotaxin inhibitors
UA107783C2 (en) Isoindoline compounds for use in treating cancer
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
SG178952A1 (en) Chemical compounds
IN2014DN10670A (es)
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
PH12015501609A1 (en) Phenicol antibacterials
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
MX2013002660A (es) Heteroarilmetilamidas.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2015011198A (es) Compuestos antivirales.
IN2014CN00572A (es)
SG10201900541QA (en) Derivatives of xanthone compounds
MX2015010790A (es) Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2015009176A (es) Derivados de triazola antivirales.